Japan’s Mitubishi Tanabe Apologizes, Settles Hepatitis C Suits
This article was originally published in PharmAsia News
Mitsubishi Tanabe's president admitted the firm's and its Benesis subsidiary's role in an outbreak of hepatitis C that infected 1.5 million people. Natsuki Hayama faced a group of Japanese who successfully sued the company for damages and the deaths of relatives and promised there would be no recurrence of the tainted blood products that led to the outbreak. Hayama apologized and promised to try to develop a new drug for treating the disease. The Japanese government earlier settled other suits, leaving Nippon Pharmaceutical the sole hepatitis C defendant yet to settle suits. (Click here for more
You may also be interested in...
The Environmental Working Group and Scientific Analytical Institute say inadequate testing of talc-containing personal-care products is to blame for findings of asbestos in cosmetics, including three of 21 powder-based cosmetics SAI analyzed at EWG’s request. They continue to push for updated testing standards that include electron microscopy as a core component.
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.